Compare Fiverr International Ltd (FVRR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Fiverr International Ltd trades at $8.98 (market cap $326.79M), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 254.6× Fiverr International Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | REGN | |
|---|---|---|
Market Cap | $326.79M | $83.19B |
Sector | Industrials | Health |
52-Week High | $26.67 | $812.27 |
52-Week Low | $8.75 | $555.51 |
Enterprise Value | $79.18M | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $9.42, up 2.39% on the day, but remains near its 52-week low amid bearish technical signals. The stock shows weak earnings momentum with Q2 2026 misses and lowered 2026 guidance due to AI disruption compressing demand for freelance services. Valuation ratios appear attractive with P/E of 11.63 and P/S of 0.83, while profitability metrics show modest improvement with net income margin at 7.18% for 2025.
The outlook is cautious with significant headwinds from AI adoption threatening Fiverr's core business model. Near-term risks include declining active buyers and revenue pressure, though current valuations may offer contrarian appeal if the company successfully adapts to AI challenges. Wall Street sentiment is neutral with 76% hold ratings and a $10.70 consensus price target suggesting limited upside.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
